Dr James Doonan

  • Orthopaedic Research Manager (Institute of Infection Immunity & Inflammation Administration)

telephone: 0141 232 0888
email: James.Doonan@glasgow.ac.uk

Publications

List by: Type | Date

Jump to: 2021 | 2020 | 2019 | 2018 | 2017 | 2016
Number of items: 7.

2021

Brown, M., Ramasubbu, R., Jenkinson, M., Doonan, J., Blyth, M. and Jones, B. (2021) Significant differences in rates of aseptic loosening between two variations of a popular total knee arthroplasty design. International Orthopaedics, (doi: 10.1007/s00264-021-05151-w) (PMID:34392378) (Early Online Publication)

2020

Crowe, J. et al. (2020) The parasitic worm product ES-62 promotes health- and life-span in a high calorie diet-accelerated mouse model of ageing. PLoS Pathogens, 16(3), e1008391. (doi: 10.1371/journal.ppat.1008391) (PMID:32163524) (PMCID:PMC7108737)

2019

Doonan, J., Tarafdar, A., Pineda, M. A. , Lumb, F. E., Crowe, J., Khan, A. M., Hoskisson, P. A., Harnett, M. M. and Harnett, W. (2019) The parasitic worm product ES-62 normalises the gut microbiota bone marrow axis in inflammatory arthritis. Nature Communications, 10, 1554. (doi: 10.1038/s41467-019-09361-0) (PMID:30952846) (PMCID:PMC6451002)

2018

Doonan, J. et al. (2018) Failure of the anti-inflammatory parasitic worm product ES-62 to provide protection in mouse models of type I diabetes, multiple sclerosis, and inflammatory bowel disease. Molecules, 23(10), 2669. (doi: 10.3390/molecules23102669) (PMID:30336585) (PMCID:PMC6222842)

Doonan, J., Lumb, F. E., Pineda, M. A. , Tarafdar, A., Crowe, J., Khan, A. M., Suckling, C. J., Harnett, M. M. and Harnett, W. (2018) Protection against arthritis by the parasitic worm product ES-62, and its drug-like small molecule analogues, is associated with inhibition of osteoclastogenesis. Frontiers in Immunology, 9, 1016. (doi: 10.3389/fimmu.2018.01016) (PMID:29867986) (PMCID:PMC5967578)

2017

Lumb, F. E., Doonan, J., Bell, K. S., Pineda, M. A. , Corbet, M., Suckling, C. J., Harnett, M. M. and Harnett, W. (2017) Dendritic cells provide a therapeutic target for synthetic small molecule analogues of the parasitic worm product, ES-62. Scientific Reports, 7(1), 1704. (doi: 10.1038/s41598-017-01651-1) (PMID:28490801) (PMCID:PMC5431997)

2016

Janicova, L., Rzepecka, J., Rodgers, D.T., Doonan, J., Bell, K.S., Lumb, F.E., Suckling, C.J., Harnett, M.M. and Harnett, W. (2016) Testing small molecule analogues of theAcanthocheilonema viteaeimmunomodulator ES-62 against clinically relevant allergens. Parasite Immunology, 38(6), pp. 340-351. (doi: 10.1111/pim.12322) (PMID:27059010) (PMCID:PMC4913752)

This list was generated on Fri Oct 15 21:22:31 2021 BST.
Jump to: Articles
Number of items: 7.

Articles

Brown, M., Ramasubbu, R., Jenkinson, M., Doonan, J., Blyth, M. and Jones, B. (2021) Significant differences in rates of aseptic loosening between two variations of a popular total knee arthroplasty design. International Orthopaedics, (doi: 10.1007/s00264-021-05151-w) (PMID:34392378) (Early Online Publication)

Crowe, J. et al. (2020) The parasitic worm product ES-62 promotes health- and life-span in a high calorie diet-accelerated mouse model of ageing. PLoS Pathogens, 16(3), e1008391. (doi: 10.1371/journal.ppat.1008391) (PMID:32163524) (PMCID:PMC7108737)

Doonan, J., Tarafdar, A., Pineda, M. A. , Lumb, F. E., Crowe, J., Khan, A. M., Hoskisson, P. A., Harnett, M. M. and Harnett, W. (2019) The parasitic worm product ES-62 normalises the gut microbiota bone marrow axis in inflammatory arthritis. Nature Communications, 10, 1554. (doi: 10.1038/s41467-019-09361-0) (PMID:30952846) (PMCID:PMC6451002)

Doonan, J. et al. (2018) Failure of the anti-inflammatory parasitic worm product ES-62 to provide protection in mouse models of type I diabetes, multiple sclerosis, and inflammatory bowel disease. Molecules, 23(10), 2669. (doi: 10.3390/molecules23102669) (PMID:30336585) (PMCID:PMC6222842)

Doonan, J., Lumb, F. E., Pineda, M. A. , Tarafdar, A., Crowe, J., Khan, A. M., Suckling, C. J., Harnett, M. M. and Harnett, W. (2018) Protection against arthritis by the parasitic worm product ES-62, and its drug-like small molecule analogues, is associated with inhibition of osteoclastogenesis. Frontiers in Immunology, 9, 1016. (doi: 10.3389/fimmu.2018.01016) (PMID:29867986) (PMCID:PMC5967578)

Lumb, F. E., Doonan, J., Bell, K. S., Pineda, M. A. , Corbet, M., Suckling, C. J., Harnett, M. M. and Harnett, W. (2017) Dendritic cells provide a therapeutic target for synthetic small molecule analogues of the parasitic worm product, ES-62. Scientific Reports, 7(1), 1704. (doi: 10.1038/s41598-017-01651-1) (PMID:28490801) (PMCID:PMC5431997)

Janicova, L., Rzepecka, J., Rodgers, D.T., Doonan, J., Bell, K.S., Lumb, F.E., Suckling, C.J., Harnett, M.M. and Harnett, W. (2016) Testing small molecule analogues of theAcanthocheilonema viteaeimmunomodulator ES-62 against clinically relevant allergens. Parasite Immunology, 38(6), pp. 340-351. (doi: 10.1111/pim.12322) (PMID:27059010) (PMCID:PMC4913752)

This list was generated on Fri Oct 15 21:22:31 2021 BST.